Clinical meaning of genetic polymorpism of CYP 2C9 in development of NSAIDs-gastropathy and gastrointestinal bleeding
- 1National Medical University named after A.A. Bogomolets, Kyiv
- 2Ukrainian Scientific-Practical Center of Endocrine Surgery, Transplantation of endocrine organs and tissues of the Ministry of Health of Ukraine, Kiev
- 3Crimea State Medical University named after S.I. George, Simferopol
Summary. The results of investigation the features of genotype СУР 2С9 in patients with NSAIDs-induced gastrointestinal bleeding are presented in the article. In conclusion, genotypes CYP 2C9*1/*3 and CYP 2C9*1/*2 are associated with high risk of gastrointestinal bleeding, whereas the presence of the genotype CYP 2C9*2/*3 is not significantly associated with this risk. CYP 2C9 genotyping may be useful in identifying the subgroup of patients with potentially higher risk of gastroduodenal bleeding when treated with NSAIDs metabolized by CYP 2C9. Further studies involving more patients to evaluate the effectiveness of CYP 2C9 genotyping in NSAID users are needed before this method will be introduced into clinical practice.